MedTrace Logo

Study on Pharmacokinetics of Hydronidone

NCT04162821 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-03-24

No results posted yet for this study

Summary

To evaluate the pharmacokinetic characteristics of hydronidone capsules (specification: 30 mg/ pill) in healthy subjects And the effect of feeding on pharmacokinetics to provide evidence for phase II/III clinical trial protocols.

Conditions

  • Pharmacokinetics of Hydronidone

Interventions

DRUG

Hydronidone

Take hydroxynitone capsule

Sponsors & Collaborators

  • Beijing Continent Pharmaceutical Co, Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-30
Primary Completion
2019-11-27
Completion
2021-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04162821 on ClinicalTrials.gov